The aim of this study was to determine whether cannabinoids have direct effects on chondrocyte nitric oxide production and cartilage proteoglycan breakdown which may be chondroprotective.
55,
, both agonists of cannabinoid receptors CB1 and CB2, were studied on chondrocyte nitric oxide (NO) production and cartilage proteoglycan breakdown. Bovine articular chondrocytes were used to study NO production. These were prepared by sequential enzymic digestion and plated directly into 24-well plates at high density (2 x 105/cm2). After 5 days they were incubated with win-55 (0.01 --10 ;LM) or anandamide (1-100 XM) in the presence or absence of interleukin lc~ (IL-lc~) (100U/ml) for 48h. NO production was determined in culture media using the Greiss reaction. Cartilage proteoglycan breakdown was determined using cultured bovine nasal cartilage explants, unstimulated or stimulated to resorb with IL-la (500U/ml) in the presence or absence of win-55 (10-100 ~.M).
Results: Both anandamide and win-55 inhibited IL-1 stimulated NO production, win-55 being the more potent inhibitor producing inhibition at 1-10 mM compared with 50-100 mM for anandamide. Preliminary studies have also shown inhibition of IL-1 stimulated cartilage proteoglycan breakdown by win-55 at 10 and 100 ~.M.
Conclusions:
Our studies indicate that cannabinoids may be chondroprotective, possibly in part by inhibition of NO production. Other workers have previously shown anti-arthritic effects of cannabinoids in animal models of arthritis which our observations suggest could be mediated by effects on chondrocyte metabolism. Interest in new therapies for arthritis is timely and the research for chondroprotective agents is the subject of many studies. Amongst the most notable is glucosamine (GIcN) (i.e. glucosamine-SO 4, glucosaniine-HCI) with the variety of studies demonstrating efficacy at modulating chondrocyte function and joint pathology. It has remained ambiguous as to whether ingested GLcN makes its way to the joint. We built on our recent in vitro experiments (A&R 44:1089-1095) , showing that cartilage explants 13 GIcN result in the detechon of cultured in medium containing C-" ' 13C in galactosarnine moieties of chondroitin sulfate. We designed a study to trace the fate of orally dosed GIcN in the dog using 13C-GIcN and the sensitive techniques of inductively coupled plasma mass spectroscopy (ICP-MS) and NMR spectroscopy. Two dogs were treated with 13C-glucosamine-HCL by oral dosing (combined with food). Dog 1 was given 500 mg/dog/day (-50 mg/kg/day) for 2 weeks and dog 2, 250 mg/dog/day for 3 weeks. Cartilage was harvested from the femoral condyles, along with liver, spleen, heart, kidney, skin, skeletal muscle, lung, and costal cartilage (treated and control S41 dogs). Tissues were prepared for ICP-MS (Perkin;Eliner E~n 6000) by digestion with nitric acid and analyzed for J~C and ~°C in triplicate (identical to 0.01%). The articular cartilage from dog 1 (high dose) showed an increase of 2.6% of 13 C compared with control and dog 2 (low dose) an increase of 1.6%. These data were confirmed by NMR spectroscopy where all five peaks in the anomeric region of 13 C NMR spectra (G1 cUA and GalNac peaks from chondroitin sulfate(CS)-4 and CS-6 and keratan sulfate, respectively) were all elevated in both treated dogs compared to controls. The 12C/13 C ratios of other tissues were analyzed to determine the distribution of 13C_G1cN. As expected, the liver had the highest 13 C percentage of the other tissues but all were less than articular cartilage. Considering the natural stability of 12C/13C ratios, rate of biosynthesis, and the single 13C per GlcN, the increases are well within the expected range if 13C-G1 cN was incorporated into proteoglycans. These results for the first time provide convincing evidence that oral GtcN is bioavailable to chondrocytes in joint cartilage thereby potentially having an affect on the available GIcN for proteoglycan biosynthesis. Results: tn base on citrate synthase activity, OA chondrocytes have more mitochondrias than normal chondrocytes (13.6%). However, the AMRCC is altered on OA chondrocytes. The activity of complex II is decreased by 3 7.6% in OA cells with regard to normal cells. These differences between OA and normal cells are independent of age. A comparative analysis by classes of age from 40 to 70 and from 70 to 90 between normal and OA chondrocytes shows a reduction in activity of complex II (about 37%). The analysis of correlation between ageing and mitochondrial activity on normal and OA chondrocytes did not show any significant association. The administration of NO as Sodium NitroPrusside (SNP), causes a reduction in activity of complex 11 (32.8%) and IV (25.5%) on normal chondrocytes. Furthermore, NO decreases the mitochondriat membrane potential by a 24% quantified by flow cytometry.
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Conclusions: These findings suggest that the alteration of complex II activity may contribute to pathological process in OA. NO is involved in pathological development of OA because it modifies the mitochondrial respiratory activity and induces a mitochondril depolarization.
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DIFFERENTIAL REGULATION OF CONNECTIVE TISSUE GROWTH FACTOR mRNA LEVELS BY TRANSFORMING GROWTH FACTOR-P AND TUMOUR NECROSIS FACTOR-c¢ IN CANINE ARTICULAR CHONDROCYTES S Richardson, SD Carter Connective 77ssue Research Group, Dept of Veterinary Pathology, University of Liverpool, Liverpool, UK
Aim: The aim of this study was to investigate the effects of TGFand TNF-c~ on expression of CTGF by normal canine articular chondrocytes maintained in alginate culture.
Methods:
Cartilage was obtained post-mortem from normal canine stifle joints. Chondrocytes were isolated by collagenase digestion, cultured to second passage in monolayer and transferred to alginate. Alginate embedded chondrocytes were stimulated with a range of doses of TGFb (0.2 -25nglml) and TNF-c~ (2 -250ng/ml), either singly or in combination for 24 hours. Canine specific CTGF primers were used in RT-PCR to examine mRNA expression.
Results: CTGF mRNA was constitutively expressed by canine chondrocytes and was significantly upregulated by TGF-I~, while TNF-c~ caused a significant decrease. Changes were found to be dose-dependant and costimulation showed an antagonistic relationship between the two cytokines.
Conclusion:
We showed CTGF mRNA to be expressed by normal canine articular chondrocytes and that its expression can be modulated by both the anabolic growth factor TGF-~ and the catabolic cytokine TNF-(z. While both TGF-~ and TNF-a have been shown to modulate CTGF expression in fibroblasts, there is no published data on its regulation in articular chondrocytes. As a downstream effector of TGF-J3 action CTGF offers a potential therapeutic target in OA as increased expression could both stimulate ECM component production and inhibit catabolic enzyme synthesis.
PA71 SUSCEPTIBILITY OF OA CARTILAGE TO THE EFFECTS OF IL-lb ARE NOT RELATED TO EXPRESSION OF EITHER THE TYPE I OR TYPE II |L-1B RECEPTOR Srinivasan MS, Elson CJ Westacott C/. University of Bristol Medical School, Bristol, UK
Introduction: Whether IL-I~ contributes to the focal loss of cartilage characteristic of osteoarthritis (OA) is not clear. The susceptibility of cartilage from different regions of OA knee joints to the effects of IL-I and its relationship with chondrocyte expression of type I, signaling, and type II, decoy, IL-113 receptors (R) was therefore examined.
Methods: Cartilage was obtained from different regions on the knees of II OA patients undergoing surgery for total knee replacement (1) and incubated for 14 days with IL-I~ (2Opg/ml). Chondrocytes were isolated by enzymatic digestion from cartilage off-cuts obtained from each region (1). Chondrocytes and HEL92 ceils, used as a positive control for IL-1 R, were stained with non-crossreacting antibodies to type 1 or type II IL-1R (Genzyine) and II.-1 R expression determined by flow cytometry.
Results: Significant regional variation was observed in susceptibility to the effects of IL-1. Differences were apparent in chondrocyte expression of the two receptor types; IL-1RI and IL-1RII expression was related. Discussion: Significant regional differences in cartilage susceptibility to the effects of IL-I were found. However, the absence of any significant relationship between the IL-IR expression and IL1b-induced GAG release from cartilage suggests that factors other than chondrocyte receptor expression influence the response of cartilage to the effects of this cytokine. Aim: To assess the effects of two antioxidants, N-monomethyl-Larginine (LNMMA) and N-acetylcysteine (NAC) on the expression of TGF-~I, 132 and 133 and their receptors I and il, using LPS-treated human chondrocytes.
Methods: Human chondrocytes were treated for 48h with LPS (10 Zg/ml), L-NMMA (0.5 mM) or NAC (1 mM). Nitrite levels were assayed using the Griess method. The expression of NO synthase (iNOS), TGF-131, 132, 133, TGF-13-.RI and II, was determined by semi-quantitative RT-PCR.
Results: LPS induced a dramatic increase of both NO and iNOS mRNA levels. L-NMMA abolished NO production without affecting iNOS mRNA levels. In contrast, NAC strongly synergized with LPS to stimulate NO synthesis. LPS did not significantly alter TGF-I31 expression whereas L-NMMA inhibited its production. TGF-132 mRNA level was decreased by LPS and was not changed by L-NMMA. On the other hand, NAC counteracted the LPSinduced inhibition of TGF-b2 expression. TGF-b3 mRNA level was markedly reduced by LPS alone, or with both LoNMMA and NAC. TGF-~RI expression was slightly increased by the combination LPS+L-NMMA or LPS+NAC whereas that of TGF~-RII was reduced in these conditions.
Conclusions:
ROS differentially control the TGF-I] system, depending on the isoform: TGF-I31 mRNA level depends on NO whereas that of TGF-132 is regulated by ROS and TGF-133 seems
